-
Key Brands
-
Statistics
-
Revenue
-
Contribution
-
Analysis
| Brand | Therapeutic category |
|---|---|
| Arixtra | Antithrombotic agent |
| Diprivan | General anaesthetic |
| Fraxiparine | Low molecular weight heparin |
| Naropin | Regional anaesthetic |
| Ultiva | Injectable general anaesthetic |
0
Products
Launched
Launched
(2021: 3)
Product
Recalls
Recalls
(2021: Nil)
10 %
Average Staff
Turnover
Turnover
(2021: 14%)
Work-related
Facilities
Facilities
(2021: Nil)
435
Sales
Representatives
Representatives
(2021: 574)
900
Permanent
Employees
Employees
(June 2021: 1,214)
| Revenue | 2022 R’million | 2021 (CER) R’million | Change % |
|---|---|---|---|
| Total Commercial Pharmaceuticals | 5 117 | 5 127 | 0 |
| Regional Brands | 613 | 614 | 0 |
| Sterile Focus Brands | 4 503 | 4 513 | 0 |
| Manufacturing – API Chemicals | 112 | 75 | 49 |
| Total | 5 228 | 5 202 | 0 |
Note: Commercial Pharmaceuticals revenue is by customer geography and manufacturing revenue by place of manufacture.
Contribution to Group revenue (%)
- Rest of Group 75
- Asia 25
Revenue by segment (%)
- Sterile Focus Brands 86
- Regional Brands 12
- Manufacturing - API Chemicals 2
- China’s pharmaceutical market including hospital and retail channels is expected to grow at 2,4% CAGR (2021 to 2026). The market is expected to be valued at RMB1,234 billion by 2026.
- The Korea total pharmaceutical market grew 8,2% MAT Q1 2022 versus Q1 MAT 2021.
Source: IQVIA Market Prognosis 2022M03 & IQVIA MAT 2022
Q1 Vs MAT 2021 Q1
MAT = Moving annual total.
